ContraFect Corporation (Nasdaq:
CFRX), a late clinical-stage biotechnology company focused
on the discovery and development of direct lytic agents (DLAs),
including lysins and amurin peptides, as new medical modalities for
the treatment of life-threatening, antibiotic-resistant infections,
announces today that the Company has been selected for an oral
presentation and six poster presentations at the 32nd European
Congress of Clinical Microbiology & Infectious Diseases
(ECCMID) Annual Meeting to be held from April 23-26, 2022 in
Lisbon, Portugal. The data being presented will feature exebacase,
the Company’s Breakthrough Therapy designated product candidate
currently being studied in a pivotal Phase 3 superiority design
study, CF-370, an engineered lysin product candidate demonstrating
potent in vitro bactericidal activity against resistant
Gram-negative pathogens, as well as lead compounds from the
Company’s proprietary amurin peptide program.
ECCMID 2022 Presentation
Details:
Session: 05. New Antibacterial Agents,
PK/PD & Stewardship5a. Mechanisms of Action,
New Compounds, Preclinical Data & Pharmacology
of Antibacterial Agents
ORAL PRESENTATION:
Title: In vivo efficacy of CF-370 alone
and in addition to amikacin in the rabbit acute pneumonia model
caused by an extensively drug-resistant (XDR) Pseudomonas
aeruginosa, AR-769
Presenting Author: Dario
Lehoux, Ph.D., Head of Preclinical Development, ContraFect
Presentation Date: Tuesday,
April 26th, Hall G; 00819
Session Time: 3:30am-5:30am
ET
Abstract ID# 00513
POSTER PRESENTATIONS:
Title: Lysin CF-370 exhibits a low propensity
for decreased susceptibility in Gram-negative (GN) ESKAPE
pathogensAvailable Online: April 23rd-26th
Poster P1296; Abstract ID #01724
Title: Lysin CF-370 suppresses in vitro
resistance in Pseudomonas aeruginosa to meropenem, tobramycin and
levofloxacinAvailable Online: April 23rd-26th
Poster P1294; Abstract ID #01730
Title: Direct lytic agents, a novel family
of antimicrobial agents, have a low propensity for decreased
susceptibility in Gram-negative pathogens associated with airway
infection in Cystic FibrosisAvailable Online:
April 23rd-26th Poster P1295; Abstract ID
#01727
Session 03. Bacterial Susceptibility &
Resistance
3a. Resistance Surveillance &
Epidemiology: MRSA, VRE & Other Gram-Positives
POSTER PRESENTATION:
Title: In vitro activity
of exebacase against contemporary beta-haemolytic streptococci
recovered from US patients with bloodstream infections
Available Online: April
23rd-26th
Poster P0496; Abstract ID#
00566
Session 03. Bacterial Susceptibility &
Resistance
3c. Susceptibility Testing Methods (Incl
Assay Validation and Comparative Studies, Excl Tb
POSTER PRESENTATIONS:
Title: Evaluation of the
broth microdilution MIC method for exebacase against 100
beta-haemolytic streptococci
Available Online: April
23rd-26th
Abstract ID# 00560; Poster;
P0771
Title: Assessment
of exebacase MIC reproducibility: Thirty S. aureus isolates tested
at three sites using three different commercial media lots
Available Online: April
23rd-26th
Poster P0772; Abstract ID #
00388
All posters will be available to meeting registrants on demand
through the ECCMID website.
Following the meeting, the presentations will be available on
the ContraFect website.
About ContraFect
ContraFect is a biotechnology company focused on
the discovery and development of DLAs, including lysins and amurin
peptides, as new medical modalities for the treatment of
life-threatening, antibiotic-resistant infections. An estimated
700,000 deaths worldwide each year are attributed to
antimicrobial-resistant infections. We intend to address life
threatening infections using our therapeutic product candidates
from our platform of DLAs, which include lysins and amurin
peptides. Lysins are a new class of DLAs which are recombinantly
produced antimicrobial proteins with a novel mechanism of action
associated with the rapid killing of target bacteria, eradication
of biofilms and synergy with conventional antibiotics. Amurin
peptides are a novel class of DLAs which exhibit broad-spectrum
activity against a wide range of antibiotic-resistant Gram-negative
pathogens, including P. aeruginosa, Acinetobacter
baumannii, and Enterobacter species. We believe that the
properties of our lysins and amurin peptides will make them
suitable for targeting antibiotic-resistant organisms, such as MRSA
and P. aeruginosa, which can cause serious infections such as
bacteremia, pneumonia and osteomyelitis. We have completed a Phase
2 clinical trial for the treatment of Staph
aureus bacteremia, including endocarditis, with our lead lysin
candidate, exebacase, which is the first lysin to enter clinical
studies in the U.S. Exebacase, currently being studied in a pivotal
Phase 3 clinical study, was granted Breakthrough Therapy
designation by the FDA for the treatment of MRSA bloodstream
infections, including right-sided endocarditis, when used in
addition to SOC anti-staphylococcal antibiotics.
Follow ContraFect on Twitter
@ContraFectCorp and
LinkedIn.
Forward-Looking Statements
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities laws.
Forward-looking statements can be identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential,” “promise” or similar references to future periods.
Examples of forward-looking statements in this release include,
without limitation, statements regarding: the ECCMID presentations
and the data being presented, ContraFect’s ability to discover and
develop DLAs as new medical modalities for the treatment of
life-threatening, antibiotic-resistant infections, whether
ContraFect will address life-threatening infections using
therapeutic candidates from its DLA platform, whether lysins are a
new class of DLAs which are recombinantly produced, antimicrobial
proteins with a novel mechanism of action associated with the rapid
killing of target bacteria, eradication of biofilms and synergy
with conventional antibiotics, whether amurins are a novel class of
DLAs which exhibit broad-spectrum activity against a wide range of
antibiotic-resistant Gram-negative pathogens, and whether the
properties of ContraFect’s lysins and amurins will make them
suitable for targeting antibiotic-resistant organisms, such as MRSA
and P. aeruginosa. Forward-looking statements are statements
that are not historical facts, nor assurances of future
performance. Instead, they are based on ContraFect’s current
beliefs, expectations and assumptions regarding the future of its
business, future plans, strategies, projections, anticipated events
and trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including the occurrence of any adverse events related to
the discovery, development and commercialization of ContraFect’s
product candidates such as unfavorable clinical trial results,
insufficient supplies of drug products, the lack of regulatory
approval, or the unsuccessful attainment or maintenance of patent
protection and other important risks detailed under the caption
“Risk Factors” in ContraFect's filings with the Securities and
Exchange Commission. Actual results may differ from those set forth
in the forward-looking statements. Important factors that could
cause actual results to differ include, among others, our ability
to develop treatments for drug-resistant infectious diseases. Any
forward-looking statement made by ContraFect in this press release
is based only on information currently available and speaks only as
of the date on which it is made. Except as required by applicable
law, ContraFect expressly disclaims any obligations to publicly
update any forward-looking statements, whether written or oral,
that may be made from time to time, whether as a result of new
information, future developments or otherwise.
Investor Relations
Contacts:
Michael MessingerContraFect CorporationTel:
914-207-2300Email: mmessinger@contrafect.com
Media:
Jules AbrahamCORE IRTel: 917-885-7378Email:
Julesa@coreir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2024 to May 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From May 2023 to May 2024